• Publications
  • Influence
Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer.
Seventy-seven patients with advanced gastric carcinoma were prospectively randomized to receive 5-FU and carmustine (FB) with or without doxorubicin (FAB). Thirty-five patients were evaluable forExpand
  • 22
Sequential methotrexate and 5-FU in breast cancer resistant to the conventional application of these drugs.
Methotrexate and 5-FU were given sequentially with a 7-hour interval to 43 evaluable patients with heavily pretreated metastatic breast cancer. Partial remissions were seen in 12 patients (28%),Expand
  • 7
Phase III Evaluation of Ftorafur within Combination Chemotherapy of Advanced Gastric and Colorectal Carcinoma
SummaryIn a prospective, multicenter, randomized trial the combination of 5-fluorouracil-carmustine with Ftorafur-carmustine in patients with advanced gastrointestinal adenocarcinoma was compared. Par
  • 1
[Sequential methotrexate and fluorouracil in metastasizing colorectal carcinomas. Results of a phase II pilot study (author's transl)].
A sequential combination of methotrexate and 5-fluorouracil was used for treatment of 20 patients with metastasizing colorectal carcinomas. Pretreatment with 5-fluorouracil had been given to fiveExpand
  • 4
Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.
AIMS To explore and to compare the outcome of patients diagnosed with stage II/III/IV and stage III/IV endometrioid adenocarcinoma (EAC) with their serous carcinoma (USC) counterparts. MATERIALSExpand
  • 7
Topically Applied Miltefosine (Hexadecylphosphocholine) in Patients with Skin-Metastasized Breast Cancer. A Phase II Study
Background: A clinical phase II study with a topical formulation of hexadecylphosphocholine (Miltefosine solution 6%) was performed in patients with skin-metas-tasized or locally re
  • 4
4′-lodo-4′-Deoxydoxorubicin (IDX) in Colorectal Cancer – A Multicenter Phase II Study
Background : Iododoxorubicin is a doxorubicin analogue with a promising antineo-plastic and toxicity profile in experimental systems. Patients and Methods : Patient
  • 1
5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
In a phase-II-trial 40 patients with advanced gastric cancer were treated with 5-fluorouracil, 4-epidoxorubicin, mitomycin C (FEM) combination therapy. Twenty-five out of 30 patients with measurableExpand
  • 5